Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

Joint development strategy has been developed to address international deployment requirements if current outbreak continues ...

CellCarta, a leading global precision medicine laboratory services provider and Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

Before turning to the quarter, I'd like to begin by recapping the Q1 announcements we highlighted on our last earnings call.

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded diagnostic response capabilities. Key Investor Takeaways ・Co-Diagnostics (NASDAQ ...

A good bioassay, like a good marriage, joins two partners in a bond and is mutually beneficial. In the case of bioassays, optimal design and development and accurate statistical analysis comprise a ...

Cancer research increasingly depends on assays that can keep pace with biological complexity, interrogating key mechanisms such as signaling pathways, enzyme activity, and cell metabolism. 1,2 As ...